Back to Search
Start Over
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
- Source :
- Journal of Clinical Oncology; 4/20/2023, Vol. 41 Issue 12, p2238-2247, 10p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Issue :
- 12
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 163135814
- Full Text :
- https://doi.org/10.1200/JCO.22.01725